About IAME
Our laboratory, entitled IAME for “Infection, Antimicrobials, Modelling, Evolution”, is an alliance from basic to clinical and population-based research towards medical progress in the fight against infectious diseases.
Created in 2014, IAME is affiliated with the French Institute for Medical Research (INSERM), the University Paris Cité (UPCité) and the University Sorbonne Paris Nord (USPN).
It is located at the UPCité Bichat Medical School campus in Northern Paris and connected to several hospitals from the Assistance Publique – Hôpitaux de Paris (AP-HP).
IAME provides a unique opportunity to mix basic scientists from various disciplines (mathematicians, statisticians, economists, bacteriologists, virologists) and clinicians involved in infectious disease research.
Key figures
IAME day, 23 May 2024
Focus on...
Papers of the month
Monkeypox clade IIb in France in 2023-2024
The Lancet Regional Health. Europe
Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case-control study
The Lancet Regional Health. Europe
News
Symposium Institut Hors Mur Microb’UP Tuesday 3rd December 2024 at the UPC Bichat Campus
On the occasion of Erick Denamur’ retirement, this symposium was a “tour de table” of what has been done during the last 25 years on the Bichat campus within his lab, in close relationships with various colleagues.
Two members of IAME among the Highly Cited Researchers
Congratulations to Jean-Francois Timsit and Yazdan Yazdanpanah
Research teams
Etienne Ruppé
Imane El Meouche
Team EVRest “Ecology, Evolution and Therapeutic of Virulence and Resistance in Bacteria”, achieves a better understanding of the ecological, evolutionary and molecular parameters allowing the adaptation of natural isolates of the Escherichia coli species to their various lifestyles, especially those involved in the emergence of virulence and antimicrobial resistance and develops new original therapeutic approaches to fight this pathogen.
Jérémie Guedj
Team MOCLID “Statistical Modelling and Clinical Investigation in Infectious Diseases”, develops statistical methods for analysis of longitudinal data obtained in clinical trials and performs clinical investigation in the treatment of infectious diseases.
Charlotte Charpentier
Jade Ghosn
Team PreViST “Pathogenesis, Treatment and Prevention strategies of Viral Infections and Sexually Transmitted Infections” is evaluating interventions designed for infectious diseases prevention, control, and care. PreViST is focusing on chronic viral infections, emerging viral infections, and bacterial and viral sexually transmitted infections. The team includes five research axes.
Naïm Ouldali
Team EPIC “REducing the burden of Pneumococcal disease In Children”, created in April 2024 as an ATIP/AVENIR INSERM team, is dedicated to epidemiological and clinical research on severe community-acquired pediatric infectious diseases. Specifically, this team addresses the issue of modelling the adaptive evolution of Streptococcus pneumoniae following human interventions and predicting the potential impact of innovative public health interventions aimed at reducing the burden of respiratory infections in children.